Hollow Fibre Infection Model
Rapidly expanding facilities for in vitro PK/PD analysis in the Hollow Fibre Infection Model in BSL2
Longer study time periods leads to understanding the PK/PD relationships and the risks of the emergence of resistance in response to a given treatment
- Antimicrobial compound/strategy
- Co-develop, Outsource, Joint Venture
Infectious disease area:
Life science company providing access to highly effective new therapeutics, leveraging its multimodality platform with unique innovative technologies
BSL3 high throughput screening capabilities, up to 400,000 compounds, against numerous pathogens including Mycobacterium tuberculosis.